Nautilus Bundle
Who Really Owns Nautilus?
Unraveling the ownership of a company is like charting a course through its strategic decisions and future prospects. Understanding who controls a company like Nautilus, Inc. reveals crucial insights into its direction and potential. This deep dive into Nautilus's ownership structure will help you understand its journey through the fitness industry.
From its origins with Arthur Jones to its current status as a publicly traded company, the Nautilus SWOT Analysis reveals a dynamic evolution. The history of Nautilus, Inc. is marked by acquisitions and rebranding, transforming it into a major player in the fitness market. Exploring the ownership of Nautilus provides essential context for investors and anyone interested in the company's financial performance and strategic positioning in the fitness industry. We will explore the key players behind Nautilus, including its founders, key investors, and the impact of public shareholders.
Who Founded Nautilus?
The story of Nautilus ownership begins with Arthur Jones, who founded the original company in 1986. Jones, a pioneer in the fitness industry, created the Nautilus exercise machines, with the first Nautilus pullover sold in 1970. He later sold the company for $23 million.
The Nautilus company we know today, focusing on fitness solutions, was established in 1997 by Nicolas Orlin. This entity, initially named Direct Fitness, acquired the Nautilus brand in January 1999, and rebranded to Nautilus Inc in 2005. The evolution of the company shows a shift from its original focus on exercise machines to a broader range of fitness products.
Understanding the early ownership structure of the current Nautilus company requires distinguishing between the original company founded by Arthur Jones and the later entity led by Nicolas Orlin. The acquisition of the Nautilus brand by Direct Fitness marks a pivotal moment in the Nautilus history.
Arthur Jones's Nautilus
Arthur Jones founded the original Nautilus company in 1986.
Nicolas Orlin's Nautilus
Nicolas Orlin founded Direct Fitness in 1997, which later became Nautilus, Inc.
Brand Acquisition
Direct Fitness acquired the Nautilus brand in January 1999.
Rebranding
Direct Fitness rebranded to Nautilus, Inc. in 2005.
Early Ownership Details
Details on the early equity split or shareholding of Nicolas Orlin at the company's inception are not readily available.
Financial Performance
For information on the Nautilus company financial performance, refer to their annual reports.
While the initial ownership details of Nicolas Orlin's company are not fully available, the acquisition of the Nautilus brand and subsequent rebranding highlight the strategic moves that shaped the company. To gain a deeper understanding of the current Nautilus ownership structure and its financial standing, it's beneficial to examine the company's recent filings and reports, and also explore the Competitors Landscape of Nautilus to understand its market position.
Key Takeaways
The Nautilus company has a rich history with two distinct phases of ownership.
- Arthur Jones founded the original company.
- Nicolas Orlin's company acquired the Nautilus brand.
- The company rebranded to Nautilus, Inc. in 2005.
- Early ownership details of Orlin's company are not fully available.
Nautilus SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Nautilus’s Ownership Changed Over Time?
The evolution of Nautilus, Inc.'s ownership structure reflects its journey as a publicly traded entity. The company went public in May 1999. A key event that impacted the company was the acquisition of Octane Fitness, LLC in December 2015, which aimed to broaden its market presence and diversify its brand portfolio. This strategic move involved a $115 million transaction, financed through a combination of an $80 million loan and existing cash reserves. Understanding the Nautilus ownership structure is key to grasping the company's trajectory.
As of April 16, 2024, there were 125,265,015 shares of common stock outstanding, showcasing the scale of the company's equity. In the life sciences sector, Nautilus Biotechnology (a separate entity) had a market cap of $97.38 million USD as of June 2025, with 126 million shares, highlighting the broader scope of the Nautilus company's related ventures. This information is crucial for anyone researching Who owns Nautilus.
| Shareholder Type | Shares Held (June 10, 2025) | Percentage of Ownership (May 2025) |
|---|---|---|
| Institutional Shareholders (Nautilus Biotechnology, Inc.) | 65,938,230 | 36.88% |
| Mutual Funds (Nautilus Biotechnology, Inc.) | - | 7.88% |
| Individual Beneficial Ownership (April 16, 2024) | Sujal Patel, 18,271,466 shares (14.5%) | - |
| Individual Beneficial Ownership (April 16, 2024) | Parag Mallick, 21,323,237 shares (16.9%) | - |
Institutional investors held a significant stake in Nautilus Biotechnology, Inc. as of June 10, 2025, with 65,938,230 shares collectively. Key institutional holders include AH Capital Management, L.L.C. (holding 17,653,917 shares as of March 31, 2025), and Perceptive Advisors Llc (holding 12,594,211 shares as of March 31, 2025). The institutional ownership remained at 36.88% in May 2025, and mutual fund holdings were unchanged at 7.88%, indicating a stable investor base. To learn more about the company's marketing approach, check out the Marketing Strategy of Nautilus.
Key Takeaways on Nautilus Ownership
Understanding the shareholder structure provides insights into the company's strategic direction and financial stability.
- Nautilus Inc became public in May 1999.
- Institutional investors hold a significant portion of Nautilus Biotechnology, Inc.
- Individual beneficial ownership is also a key factor.
- The acquisition of Octane Fitness, LLC was a pivotal moment in Nautilus history.
Nautilus PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Nautilus’s Board?
The current board of directors for the Nautilus company oversees its operations. As of April 16, 2024, each share of common stock outstanding is entitled to one vote per share on all matters voted on by the shareholders, including the election of directors. Shareholders do not have the right to cumulate their votes. A majority of the outstanding shares of common stock is required to establish a quorum at the annual meeting.
As of April 29, 2021, the board included James 'Jim' Barr IV, who joined as Chief Executive Officer and Board Member in July 2019, and Carl Johnson III, who joined the board in July 2010 and has been Chairman since 2011. Matthew L. Posard has served on the board and as Chairperson since June 2021. Melissa Epperly has also served on the board since June 2021. For a deeper dive into the company's background, consider reading the Brief History of Nautilus.
| Director | Title | Since |
|---|---|---|
| Matthew L. Posard | Chairperson | June 2021 |
| Melissa Epperly | Director | June 2021 |
| James 'Jim' Barr IV | Chief Executive Officer and Board Member | July 2019 |
For the 2025 annual meeting, Nautilus Biotechnology announced changes to its board of directors, with Vijay Pande and Michael Altman stepping down and Matthew McIlwain transitioning to a Class I director. The board unanimously recommends voting 'FOR' each nominee for election as director. If specific instructions are not provided, shares will be voted in accordance with the board's recommendations.
Voting Power and Board Changes
Shareholders have one vote per share, with a majority needed for a quorum. Recent changes include directors stepping down and new appointments. Understanding the board's composition is crucial for assessing Nautilus ownership and its future direction.
- Board members oversee company operations.
- Shareholders vote on key matters.
- Changes in the board reflect strategic shifts.
- Voting aligns with board recommendations.
Nautilus Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Nautilus’s Ownership Landscape?
In a notable shift, on November 1, 2023, Nautilus Inc. rebranded itself as BowFlex, Inc. This change preceded a significant event on March 5, 2024, when BowFlex filed for bankruptcy. Subsequently, JohnsonHealthTech acquired the BowFlex, Schwinn, and JRNY brands.
Focusing on proteomics, Nautilus Biotechnology, Inc. has experienced changes in its ownership and operational strategies. As of February 27, 2025, the company reduced its workforce by 16%, impacting 25 employees. This restructuring aims to align resources with development objectives and extend its financial runway through 2027. The company reported a net loss of $18.7 million for Q1 2024; for Q1 2025, operating expenses decreased by 13% to $18.8 million, and the net loss was $16.6 million. As of March 31, 2025, Nautilus Biotechnology held $192.8 million in cash, cash equivalents, and investments.
| Metric | Q1 2024 | Q1 2025 |
|---|---|---|
| Operating Expenses | N/A | $18.8 million |
| Net Loss | $18.7 million | $16.6 million |
| Cash, Cash Equivalents, and Investments (as of March 31, 2025) | N/A | $192.8 million |
Institutional investors in Nautilus Biotechnology, Inc. decreased their holdings by 0.8337% in May 2025. Insider transactions in 2024 included sales by several individuals on June 17, 2024, and purchases by Sujal M. Patel in March 2024. These developments reflect ongoing adjustments in the ownership structure and operational strategies of the company.
Ownership Changes
BowFlex, Inc. filed for bankruptcy in March 2024, leading to an acquisition by JohnsonHealthTech. Institutional investors decreased their holdings in Nautilus Biotechnology, Inc. in May 2025. Insider transactions occurred in 2024.
Financial Performance
Nautilus Biotechnology, Inc. reported a net loss for Q1 2024 and Q1 2025. Operating expenses decreased by 13% in Q1 2025. The company holds $192.8 million in cash, equivalents, and investments as of March 31, 2025.
Operational Adjustments
Nautilus Biotechnology, Inc. reduced its workforce by 16% in February 2025. This restructuring aimed to align resources with development goals. The company is working to extend its cash runway through 2027.
Strategic Focus
The company is concentrating on proteomics research. The changes reflect efforts to optimize operations. These strategic moves aim to improve financial stability and growth.
Nautilus Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Nautilus Company?
- What is Competitive Landscape of Nautilus Company?
- What is Growth Strategy and Future Prospects of Nautilus Company?
- How Does Nautilus Company Work?
- What is Sales and Marketing Strategy of Nautilus Company?
- What is Brief History of Nautilus Company?
- What is Customer Demographics and Target Market of Nautilus Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.